Following two 12-week studies, the FDA has approved the first ever medication for treating agitation in patients with dementia due to Alzheimer disease.
Findings from 2 trials that compared various doses of the atypical antipsychotic brexpiprazole with placebo have indicated that the drug may have additional benefits for patients with agitation due to...
Researchers recently compared the effects of treatment with an atypical antipsychotic vs placebo for various periods of time among patients with Alzheimer disease psychosis.
Agitation is one of the most challenging symptoms of Alzheimer disease—for both clinicians and caregivers. This FAQ answers the most common questions about recognizing, managing, and treating agitation,...
